Cassava Sciences | PTIE - Interest Expense On Debt


Cassava Sciences reported $129.73M in Interest Expense on Debt for its fiscal quarter ending in September of 2025.





Interest Expense On Debt Change Date
Abbott USD 42M 2M Dec/2025
Amgen USD 653M 32M Dec/2025
Biogen USD 72.6M 12.6M Jun/2025
Cara Therapeutics 43.75M 4.8M Jun/2025
Cassava Sciences USD 129.73M 5.65M Sep/2025
Eisai JPY 1.43B 12M Dec/2025
Eli Lilly USD 114.7M 134.3M Sep/2025
Geron USD 8.64M 128K Sep/2025
J&J USD 18M 290M Sep/2025
Merck USD 412M 85M Dec/2025
Novartis USD 281M 8M Sep/2025
Novavax USD 4.24M 96K Sep/2024
Pfizer USD 711M 59M Dec/2025
Roche Holding CHF 304M 7.5M Jun/2025